Pacific Biosciences of California Inc (NASDAQ: PACB) on Monday, plunged -2.86% from the previous trading day, before settling in for the closing price of $1.75. Within the past 52 weeks, PACB’s price has moved between $1.16 and $10.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 24.48% over the past five years. The company achieved an average annual earnings per share of 5.17%. With a float of $259.95 million, this company’s outstanding shares have now reached $267.74 million.
Let’s look at the performance matrix of the company that is accounted for 796 employees.
Pacific Biosciences of California Inc (PACB) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Pacific Biosciences of California Inc is 4.61%, while institutional ownership is 83.96%. The most recent insider transaction that took place on Sep 30 ’24, was worth 34,061. Before that another transaction happened on Sep 16 ’24, when Company’s See Remarks sold 98,907 for $1.75, making the entire transaction worth $172,692. This insider now owns 2,497,763 shares in total.
Pacific Biosciences of California Inc (PACB) Performance Highlights and Predictions
#####
According to the Wall Street analysts, stocks earnings will be around 5.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Pacific Biosciences of California Inc (PACB) is currently performing well based on its current performance indicators. A quick ratio of 7.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.50, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Pacific Biosciences of California Inc (NASDAQ: PACB) saw its 5-day average volume 6.76 million, a negative change from its year-to-date volume of 9.58 million. As of the previous 9 days, the stock’s Stochastic %D was 28.70%. Additionally, its Average True Range was 0.17.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 35.76%, which indicates a significant increase from 23.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.40% in the past 14 days, which was lower than the 116.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6731, while its 200-day Moving Average is $3.5359. Nevertheless, the first resistance level for the watch stands at $1.7833 in the near term. At $1.8667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9133. If the price goes on to break the first support level at $1.6533, it is likely to go to the next support level at $1.6067. Assuming the price breaks the second support level, the third support level stands at $1.5233.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
Market capitalization of the company is 463.30 million based on 272,356K outstanding shares. Right now, sales total 200,520 K and income totals -306,740 K. The company made 36,010 K in profit during its latest quarter, and -173,320 K in sales during its previous quarter.
